key: cord-0703674-kn0dlgh7 authors: Dzik, Sunny; Editor, title: COVID-19 Convalescent Plasma: Now Is the Time for Better Science date: 2020-04-23 journal: Transfus Med Rev DOI: 10.1016/j.tmrv.2020.04.002 sha: 6593c62199ad9d3bdc6a68955c04f7b222f9458c doc_id: 703674 cord_uid: kn0dlgh7 nan J o u r n a l P r e -p r o o f system. Consideration of the possible harms is important for research equipoise and informed consent; and serves to remind us of the ultimate importance of good scientific method. Controlled trials bring the opportunity to address four areas of potential concern. Transfusion-associated circulatory overload (TACO) is now recognized as the most common serious adverse effect of transfusion. Hemovigilance systems-known to grossly underestimate the true incidence of adverse events-suggest that TACO may occur in as many as 12% of atrisk patient populations (3) . The incidence of TACO would be expected to be even higher in elderly COVID-19 patients with acute lung injury who are being supported with mechanical ventilation. This may be especially relevant in the setting of the pulmonary inflammation and increased vascular permeability that characterize SARS-CoV-2 infection. TACO may be particularly relevant for those patients with viral myocarditis (4) . Recent data indicate that myocardial injury is present in some patients with COVID-19 and is associated with adult respiratory distress syndrome and increased mortality (5) . The 'dose' of plasma being considered for CCP is well within the range known to be associated with TACO (6, 7, 8) in non-COVID-19 patients. J o u r n a l P r e -p r o o f complement receptors. Whether or not such a mechanism enhances viral infection of lymphocytes (rich in complement receptors) causing the lymphopenia now being observed in COVID-19 patients is not yet known. Antibody-dependent enhancement (ADE) is a well-recognized effect in many viral illnesses 12, 13) . It is characterized either as the facilitation of viral entry into cells by antibody, or the enhancement by antibody of viral toxicity. ADE is traditionally said to occur when antibody levels are insufficient to fully block viral entry but are sufficient to opsonize virus. Antibody coated virus is then drawn into cells bearing Fc receptors, including monocytes and macrophages. Pulmonary macrophages are central to the inflammatory response in COVID-19 infection and so considerations of ADE are relevant. The concept of ADE for SARS-CoV-2 is shown in Figure 1 . [ place figure 1 here ] ADE has been suggested as one explanation (among several others) for the observation that older adults, who may have seen prior strains of a given virus, can have worse infection than young children without prior exposure-a clinical observation seen in COVID- 19 . ADE has been demonstrated to occur in human clinical dengue virus infection (14) , is a well-recognized concern in vaccine research, and may be relevant for studies using CCP as prophylaxis in uninfected high-risk groups such as healthcare workers. We do not know yet whether ADE plays a role in COVID-19, but the following studies on ADE are relevant to concerns regarding the safety of patients infected with SARS-CoV-2 being considered for CCP infusions. (21) . One of the themes of the many studies on ADE is that an antibody may be classified as 'neutralizing' but can still result in adverse clinical effects. Estimates of the number of individuals who will be hospitalized for COVID-19 infection worldwide is astronomical. Given the failure of hyperimmune globulin in randomized controlled trials to improve outcomes in influenza A (25, 26) or in respiratory syncytial virus, (27) and given the absence of any randomized trials of convalescent plasma for any other viral disease, it is reasonable to imagine that 1-2 units of CCP in COVID-19 will have no meaningful benefit. Establishing lack of efficacy through controlled clinical trials takes on immense importance. In addition to offering false hope to patients, widespread application of CCP therapy prior to establishing a clear and objective measure of its efficacy through randomized trials risks diverting an enormous amount of resources away from other priorities in the pandemic. Test kits for infection and assays for neutralizing antibody levels which will likely be used to screen CCP donors are critical resources that will be diverted away from patient care or public health testing. Resources and equipment of blood collection agencies tasked with production of CCP stocks are resources that will not be used for the collection of the volunteer blood supply. The size of the potential diversion is worthy of investigation by mathematical modeling as the overall number of CCP donors evaluated and bled could be extremely high. If J o u r n a l P r e -p r o o f CCP is not harmful but is also found to be of no clinical value, mass donations of an experimental biologic outside the context of trials will have been an unforgiveable waste of resources. On the other hand, if passive immunoglobulin infusions are shown to have benefit, such information would provide valuable evidence to support the development of hyperimmune globulin preparations either derived from pools of CCP or prepared from engineered antibody produced in vitro. Such preparations are more likely to administer an effective dose than individual doses of CCP. COVID-19 represents a historic challenge to healthcare worldwide. In wealthy nations, COVID-19 patients will be receiving multiple therapeutic interventions simultaneously including other experimental therapies in addition to CCP. This fact makes randomization essential because only randomized trials will balance the very large number of confounders that exist in such complex care settings. Without the benefit of randomized controlled trials, it will be nearly impossible to understand the benefit, lack of benefit, risk, or comparative value of CCP. This is indeed a critical moment for all of us. On behalf of patients and their families, devoted healthcare workers, unselfish blood donors worldwide, and society at large, we rise to applaud those investigators from around the world who are showing leadership through the conduct of randomized trials. Some examples of emerging CCP research trials are presented in a companion paper in this issue of Transfusion Medicine Reviews. For those trials of sufficiently similar design, there would be an outstanding opportunity for researchers to work together to combine outcome analyses. We wish the investigators great success in their work. This is not Figure 1 Convalescent plasma: therapeutic hope or hopeless strategy in the SARS-CoV-2 pandemic Effectiveness of convalescent plasma therapy in severe COVID-19 patients Transfusion-associated circulatory overload: a clinical perspective COVID-19 and the cardiovascular system Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China A retrospective review of patient factors, transfusion practices, and outcomes in patients with transfusion-associated circulatory overload Transfusion-associated circulatory overload in Ireland: a review of cases reported to the National Haemovigilance office Revised international surveillance case definition of transfusion-associated circulatory overload: a classification agreement validation study Viral-induced enhanced disease illness Fc receptors in antibodydependent enhancement of viral infections Antibodydependent enhancement of severe dengue disease in humans Antibody responses against SARS coronavirus are correlated with disease outcome of infected individuals Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019 Anti-spike IgG causes severe acute lung injury by skewing macrophage responses during acute SARS-CoV infection Antibody-dependent SARS coronavirus infection is mediated by antibodies against spike proteins Molecular mechanism for antibodydependent enhancement of coronavirus entry Understanding SARS-CoV-2 mediated inflammatory responses: from mechanisms to potential therapeutic tools Relationship between the ABO blood group and the COVID-19 susceptibility Inhibition of the interaction between the SARS-CoV Spike protein and its cellular receptor by anti-histo-blood group antibodies Antiinfluenza hyperimmune intravenous immunoglobulin for adults with influenza A or B infection (FLU-IVIG): a double-blind, randomized, placebo-controlled trial Hyperimmune IV immunoglobulin treatment: a multicenter double-blind randomized controlled trial for patients with severe 2009 influenza A (H1N1) infection Respiratory syncytial virus immune globulin treatment of RSV lower respiratory tract infection in previously healthy children Figure 1: Two putative pathways for SARS-CoV-2 entry into human cells Viral Spike glycoproteins attach to receptors on host tissue (bottom left) CoV-2, the host receptor is considered to be angiotensin-converting enzyme 2 (ACE2) expressed on mucosal cells. A second pathway of viral entry (right) depends on antibody to virus and is referred to as antibody dependent enhancement (ADE)